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Background: A database for studies used for U.S. Environmental Protection Agency (EPA) 
 pesticide and chemical reviews would be an excellent resource for increasing transparency and 
improving systematic assessments of pesticides and chemicals. There is increased demand for 
 disclosure of raw data from studies used by the U.S. EPA in these reviews.
oBjectives: Because the Information Quality Act (IQA) of 2001 provides an avenue for request 
of raw data, we reviewed all IQA requests to the U.S. EPA in 2002–2012 and the U.S. EPA’s 
responses. We identified other mechanisms to access such data: public access databases, the Freedom 
of Information Act (FOIA), and reanalysis by a third party.
discussion: Only two IQA requests to the U.S. EPA were for raw data. Both of these were fulfilled 
under FOIA, not the IQA. Barriers to the U.S. EPA’s proactive collection of all such data include 
costs to the U.S. EPA and researchers, significant time burdens for researchers, and major regulatory 
delays. The U.S. EPA regulatory authority in this area is weak, especially for research conducted in 
the past, not funded by the U.S. government, and/or conducted abroad. The U.S. EPA is also 
constrained by industry confidential business information (CBI) claims for regulatory testing data 
under U.S. chemical and pesticide laws. The National Institutes of Health Clinical Trials database 
systematically collects statistical data about clinical trials but not raw data; this database may be a 
model for data from studies of chemicals and pesticides.
conclusions: A database that registers studies and obtains systematic sets of parameters and results 
would be more feasible than a system that attempts to make all raw data available proactively. Such 
a proposal would not obviate rights under the IQA to obtain raw data at a later point.
key words: access to information; chemicals, hazardous; pesticides; review, systematic. Environ 
Health Perspect 121:149–152 (2013). http://dx.doi.org/10.1289/ehp.1206101 [Online 
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The U.S. Environmental Protection Agency 
(EPA) is one among many agencies covered 
by the Information Quality Act (IQA 2001), 
an amendment to the Treasury and General 
Government Appropriations Act for fiscal year 
2001 that has been viewed as a mechanism to 
increase access to such information and to seek 
corrections if parties think that government 
agencies have used faulty information and 
analyses. The Office of Management and 
Budget (OMB) issued IQA guidelines that 
apply to all agencies in the Executive Branch: 
When these agencies provide “influential scien­
tific, financial, or statistical information,” they 
also “shall include a high degree of transparency 
about data and methods to facilitate the repro­
ducibility of such information by qualified 
third parties” (OMB 2002). The law was 
enacted without debate or hearing. In the 
absence of an extensive legislative history and 
because both the IQA and OMB guidelines 
were silent about whether agency responses 
were judicially reviewable, some had viewed 
the act as providing a new avenue for legal 
challenges of agency decisions across the U.S. 
government. For example, in 2006 the U.S. 
Fourth Circuit Court of Appeals ruled that 
plaintiffs did not have standing to sue the 
Department of Health and Human Services 
under Title III of the IQA to compel access 
to a study conducted by the National Heart, 
Lung, and Blood Institute (NHLBI) that 
was used to support action by the Food and 
Drug Administration (FDA) on dietary salt 
(Salt Institute v. Leavitt 2006). A number of 
industry groups had petitioned the NHLBI to 
make the raw data from the study available so 
that they could do subgroup reanalyses. The 
court found that the plaintiffs had received no 
injury from being denied access to the NHLBI 
data and thus did not have standing. However, 
the court also noted that the petitioners had a 
long standing right to request the raw data from 
the study using the Freedom of Information 
Act (FOIA 1966). In its response, the NHLBI 
noted that it was preparing a public access data 
set for release, which it later made available 
(NHLBI 2005). Although this case was 
resolved under existing FOIA mechanisms, 
in the wake of this litigation there has been 
concern that the IQA does not provide outside 
parties sufficient access to the data for studies 
that underlie regulatory decisions made by 
U.S. government agencies. There is increasing 
interest in improving the methods by which 
chemical and pesticide hazards and risks are 
evaluated not only by government but also 
by independent scien tists (Bucher et al. 2011; 
Woodruff et al. 2011). This interest has 
spurred increased demand for transparency and 
disclosure of the data used by the U.S. EPA 
to make evalua tions that support regulatory 
decisions for chemicals and pesticides. In this 
context, we examine the role of the IQA in 
making such data more accessible and suggest 
alternative approaches.
Review of Requests for Data
To find out how responsive the U.S. EPA 
has been to requests for raw data under the 
IQA, we reviewed 79 requests filed with the 
U.S. EPA between 2002 and 2012 either 
to correct or to reconsider the data that the 
U.S. EPA used in evaluations supporting its 
regulatory decisions during that period. Under 
OMB guidance for the IQA (OMB 2002), 
parties can request that agencies reconsider 
or correct any information used to support 
regulatory decisions; usually these requests 
are made in the form of letters. The U.S. EPA 
posted these 79 requests on its web site, 
according to OMB guidelines (U.S. EPA 
2012a). Interestingly, only two of these 
requested raw data.
The first request for raw data was filed 
in December 2003 by the Perchlorate Study 
Group, an industry consortium of manu­
facturers and users of perchlorate (Aerojet, 
American Pacific Corporation, Kerr­McGee 
Chemical, and Lockheed Martin). They 
requested that the U.S. EPA provide raw data 
from experimental studies (Girard 2003). The 
U.S. EPA granted this request in September 
2004 and provided access to brain images and 
contractor’s reports (Gilman 2003). 
The second case was filed by the Association 
of Battery Recyclers (ABR) in October 2008 
(Steinwurtzel 2008). Now called America’s 
Battery Recyclers, and formerly called the 
Secondary Lead Smelters Association, the 
ABR is a group of auto and industrial battery 
recyclers, primary lead producers, and users 
of recycled lead (America’s Battery Recyclers 
2012). The ABR requested raw data from a 
study of lead toxicity (Lanphear et al. 2005) 
that was among several published studies relied 
upon by the U.S. EPA in its development of 
the National Ambient Air Quality Standard 
(NAAQS) for lead under the Clean Air Act 
Amendments (1990). Because the ABR and 
others had taken the U.S. EPA to court to 
overturn the lead NAAQ rule at the same 
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time, the U.S. EPA opted to postpone consid­
eration of the request under the IQA pending 
the decision of the court. In its response to 
the request, the U.S. EPA noted that con­
cerns about the data analysis had been noted 
in comments during the rule­making process 
and that the U.S. EPA had commissioned new 
external peer reviews of the study (U.S. EPA 
2012a) in addition to a reanalysis of the data of 
Lanphear et al. (Rothenberg and Rothenberg 
2005). After the lead NAAQS was upheld 
in July 2010, the ABR again requested that 
the U.S. EPA provide access to the Lanphear 
data (Steinwurtzel 2010). Meanwhile, litiga­
tion was filed over the delay in providing the 
data. This litigation was dropped when the 
U.S. EPA FOIA office worked out an agree­
ment with the Cincinnati Children’s Medical 
Center to obtain the Lanphear study data 
(Lanphear BP, personal communication; Pohl 
v. U.S. EPA et al. 2012). U.S. EPA attor­
neys determined that access to the data was 
required under the 1998 Shelby Amendment, 
which makes federally funded research data 
accessible to the public under FOIA (Treasury 
and General Government Appropriations 
Appropriations Act 1998). Thus, as for the 
request to the NHLBI to provide data con­
cerning the salt study (Salt Institute v. Leavitt 
2006), the reso lu tion of the request was man­
aged under FOIA.
Because requests for raw data are few 
and far between, it has not been onerous for 
the U.S. EPA to provide such data. Existing 
mecha nisms have provided the ability to reana­
lyze data by a) development and availability of 
a public­access database (with suitable protec­
tions for the human subjects involved in such 
studies); b) provision of raw data via FOIA, for 
cases in which data are in possession of or can 
be obtained by the agency (e.g., the perchlorate 
case cited above); and c) reanalysis of data by a 
third party. As an example of the third mecha­
nism, the widely publicized results from the 
Harvard Six Cities Study (Dockery et al. 1993) 
were used by the U.S. EPA in 1997 as a basis 
for developing new standards for fine particu­
late matter (≤ 2.5 µm in aero dynamic diam­
eter) air pollution (U.S. EPA 1997). Interested 
parties, mostly from industry, raised questions 
about study analysis and interpretation. The 
raw data were not in the possession of the 
U.S. EPA, and the U.S. EPA could not compel 
the submission of these data from Harvard 
University or the funding source, the American 
Cancer Society. Under pressure from govern­
ment agencies and industry, Harvard and the 
American Cancer Society voluntarily requested 
that the Health Effects Institute (HEI) step in 
as a third party to supervise a reanalysis of their 
data. The HEI [a consortium of industry, aca­
demic, and govern ment scientists established 
by the Clean Air Act Amendments (1990)] 
provided the data for reanalysis by a third party 
selected by a science advisory committee that 
included representation from interested parties 
who had argued for an independent reanalysis, 
thus providing a process to address the uncer­
tainties about the analysis and interpretation 
(HEI 2000).
Discussion
Over time, the U.S. EPA has come to rely 
increasingly on a large number of scien­
tific studies to complete reviews for a single 
chemi cal. This is illustrated by the case of 
2,3,7,8­TCDD (2,3,7,8­tetra chloro dibenzo­
p­dioxin). In its recent assessment of TCDD, 
the U.S. EPA identified some 2,000 studies 
directly relevant to its review of dioxin toxicity. 
From these, the U.S. EPA selected 10 “key” 
epidemiologic studies and 74 “key” experi­
mental animal studies. Even for this smaller 
subset of “key” studies, the raw data for each 
human study and animal experi ment are sub­
stantial, and most of the data on TCDD were 
not in the possession of the U.S. EPA (2012b). 
There are several mechanisms through 
which the U.S. EPA might obtain these data. 
The U.S. EPA could require that investiga­
tors submit their raw data to the agency upon 
completion of their research as a condition 
of U.S. EPA funding, but this would not 
completely solve the problem. Most research 
evaluated by the U.S. EPA for regulatory deci­
sion making is not funded by the U.S. EPA. 
In these cases, the U.S. EPA would have to 
undertake an extensive collection of raw data 
from study investigators, which would be 
costly to the U.S. EPA and burdensome to 
the research community. Not insignificantly, 
this would create major delays in rule mak­
ing. In terms of resource allocation, it is rea­
sonable to ask how much of the U.S. EPA’s 
budget could be allocated to accomplish this, 
and where this would rank relative to other 
priorities, such as increasing the numbers of 
priority assessments to meet the U.S. EPA’s 
statutory goals. 
In addition to the burden on the U.S. EPA, 
there would be a significant burden on the 
scientific community that produces most of 
the relevant research, and it is very likely that 
there would be significant pushback from the 
academic community under the Paperwork 
Reduction Act (1995). In fact, the Paperwork 
Reduction Act, which was enacted to reduce 
the total amount of paperwork handled by 
the U.S. government, would not allow the 
U.S. EPA to undertake such a massive data 
collection without establishing that the bur­
den imposed upon the research community 
would be justified by the benefits of providing 
the data. 
At the least, scientists would need funding 
to respond to requests that are generated as 
a consequence of the use of their studies by 
the U.S. EPA rather than any action taken 
by the investigators themselves. Burdened by 
other responsibilities and unable to fund such 
activities from grants provided by sources 
other than the U.S. EPA, scientists are not 
likely to voluntarily provide the U.S. EPA 
with raw data from studies conducted months 
to decades in the past simply because the 
U.S. EPA has decided to include those studies 
in their latest assessment. 
Moreover, the U.S. EPA would not have 
clear legal authority to compel the submis­
sion of data from industry, federally funded 
studies conducted prior to the 1998 Shelby 
Amendment, studies funded by other federal 
agencies, or studies that are not funded by 
the U.S. government, including studies from 
non­U.S. investigators. We therefore con­
clude that a regulatory approach, in which 
the U.S. EPA compels the submission of raw 
data for all studies reviewed for rule making 
on pesticides and chemicals, would not be 
tenable. It could in fact have a chilling effect 
on the engagement of the global scientific 
community in research rele vant to the protec­
tion of human health and the environment. 
Certainly, this is not in the best interests of 
science­based policy.
In addition, there are other feasibility 
issues. In the case of older studies, raw data 
may not exist or may be difficult to access 
because of storage on outdated media such as 
tapes. For epidemiologic studies, considera­
tion would need to be given to ethical issues 
governing studies of human subjects. These 
include protection of confidentiality and pri­
vacy, and prevention of abuse of the data, for 
example, by marketing companies who may 
wish to identify patients with particular medi­
cal conditions. Clinical­trials investigators have 
been working for years to develop ways to 
disclose data from human studies, including 
mechanisms for placing data behind a bar­
rier to universal access, so that it is accessible 
only to those who meet conditions of use. In 
the case of clinical trials, there are studies in 
which removal of all identifying data negates 
its scientific value; therefore access to the data 
would need to be limited to protect privacy 
(Hrynaszkiewicz et al. 2010). With adequate 
resources and planning, these obstacles could 
be anticipated and/or overcome.
In the case of research data concerning 
chemicals and pesticides, the U.S. EPA also 
is constrained by legal constructs that have 
defined regulatory testing of pesticides as 
“confidential business information” (CBI) 
and that require the U.S. EPA to redact cer­
tain data and obtain affirmations from recipi­
ents that they will not give the remaining 
data to multi national companies that might 
seek to register the pesticide to market it in 
other countries (U.S. EPA Office of Pesticide 
Programs 2010). The U.S. EPA could improve 
the web access to summaries and analyses of 
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these data, which are publically available but 
often difficult to find in web searches. This 
would not be the same as providing access 
to raw data. We therefore suggest that, in 
the short run, industry should work with the 
U.S. EPA to identify approaches to provide 
more robust data sets for studies that they 
submit to the U.S. EPA. The U.S. EPA also 
could invite companies to voluntarily waive 
CBI claims on tests of pesticides and chemi­
cals. In the long run, we think that Congress 
should amend the Toxic Substances Control 
Act (1976) and the Federal Insecticide, 
Fungicide, and Rodenticide Act (1972) as 
amended by the Food Quality Protection Act 
(1996) to ease CBI protections from pesticide 
and chemical test data. 
In an ideal world we would always favor 
more disclosure over less, but it is not clear 
how this should be done, or who should pay 
for it. The HEI, which has an independent 
governing board and is supported by a con­
sortium of funders including the U.S. EPA 
and the automobile and petro chemical indus­
tries, may be a useful precedent. The HEI 
requires that data from all HEI­funded studies 
be made available as expeditiously as possible, 
[taking] into consideration the legitimate intel­
lectual interests of the investigator to have the 
opportunity to benefit from his or her intellectual 
endeavors and to publish subsequent analyses from 
the data set (including additional analyses funded 
by HEI). (HEI 2010) 
The HEI attempts to balance the interests 
of investigators with those of interested par­
ties in cases of “studies of particularly high 
regulatory importance being used to inform 
decisions over a short time frame,” and 
encourages its principal investigators to share 
the data except in situations where “providing 
the data would place an undue burden on the 
investigator” (HEI 2010). For example, in 
cases when there have been so many requests 
that it was difficult for the investigators to 
continue their research, the HEI has assisted 
investigators with data sharing. In addition, 
the HEI requires that data requesters pro­
vide “reasonable reimbursement for both the 
direct costs of providing the data, and for the 
time of the investigator and/or HEI staff to 
gather, transmit, and explicate the data” (HEI 
2010). HEI also “will consider requests from 
the investigator for a reasonable budget of 
data archiving funds, to be provided as part 
of the project budget” (HEI 2010). From 
this precedent, it seems that proponents of 
increased access to raw data need to consider 
not only financial and time burdens on inves­
tigators, but also a way to reasonably balance 
the need for data access with the ability of 
investigators to realize the fruits of their own 
intellectual endeavors.
Another useful precedent that could serve 
as a model for data sharing is the National 
Institutes of Health (NIH) clinical trials 
database (ClinicalTrials.gov; NIH 2012). It 
does not contain “raw data” but rather con­
tains detailed and useful information about 
 clinical­trial study designs and statistics that not 
only convey results in a standardized fashion 
but also identify important quality parameters 
(e.g., drop­out rates). Required by law (Section 
113 of the Food and Drug Administration 
Modernization Act 1997), the clinical trials 
database was developed by the NIH with input 
from the FDA and the National Library of 
Medicine (NLM). Currently, many medi­
cal journals require that trials be registered in 
ClinicalTrials.gov prior to their publication; 
as of 3 December 2012, 136,605 studies in 
182 countries were registered. Although many 
researchers are now are calling for access to raw 
data for all clinical trials (Gotzsche 2011), the 
ClinicalTrials.gov database has greatly increased 
access to information about drug efficacy trials 
and drug safety, and the develop ment of such a 
database for studies of chemicals and pesticides 
would be a major step toward increasing the 
transparency of the U.S. EPA’s evaluations and 
making data more accessible to third parties.
Conclusions
At present, there does not seem to be a large 
demand for raw data related to U.S. EPA 
decision making; however, this may change 
as formal evidentiary reviews of environ­
mental health research become increasingly 
common (Maull et al. 2012). Compared with 
clinical trials, the acquisition of raw data for 
chemicals and pesticides would be much more 
complex, in part because it would require a 
framework that can accommodate data from 
numerous types of studies: observational and 
experi mental, animal, human, in vitro, and 
high throughput screening studies. 
For human epidemiologic studies, clear 
and complete documentation would need to 
be provided for interpretation of the variables 
collected in such studies. This is no simple task 
given, for example, a) the wide range of pos­
sible study designs and the intricacies of design 
of questionnaires and subsequent coding and 
transformation of variables; b) environ mental 
and biomarker sample­collection procedures, 
chain­of­custody and sample processing and 
storage, labora tory analyses, data analysis, and 
coding; and c) imputation of missing vari­
ables or laboratory non detects. Although it is 
a standard practice to carefully document all 
of these details, there is currently no gener­
ally agreed­on manner in which to upload 
such data into an electronic database. There 
is a risk that people who were not involved in 
data collection can misunder stand these details 
and thus obtain erroneous results. Some effort 
would be required to develop a standardized 
system for reporting this kind of information. 
For experimental animal studies, there should 
be parameters related to quality assessment 
(e.g., blinding of investigators, randomization, 
housing and care of animals). 
If the U.S. EPA chose this path, the first 
step might be to develop a framework simi­
lar to ClinicalTrials.gov that would capture 
statistics and other parameters but would not 
necessarily require uploading raw data. With 
adequate funding, involvement of the NLM 
might provide more sophisticated informat­
ics expertise to make the data more usable, 
and the NLM or the National Toxicology 
Program (NTP) could perhaps provide a 
“home” for the data. The U.S. EPA and other 
environmental agencies could also require (or 
request) that investigators register their studies 
with the database, and journals could require 
registration as a condition of publication (as 
some journals currently do for results of clini­
cal trials) or suggest that it be done. Given 
resource limitations, especially for investigators 
in developing countries, this step might be 
difficult for many investigators compared with 
researchers who perform clinical trials. 
A system that provides raw data might 
be possible if the U.S. EPA could pilot the 
develop ment of a system that could handle 
raw data using data already in its possession 
[e.g., results of its intra mural research, results 
of U.S. EPA­funded extramural research 
(where available), and any raw data that it 
has requested from investigators in support 
of risk­assessment activities]. Other federal 
agencies, such as the NTP and the National 
Institute for Occupational Safety and Health 
could contribute as well. The NTP already 
publishes all of its data and methods in its 
reports; however, it does not publish raw data 
or studies with non standard protocols online. 
In any case, busy investigators may oppose this 
not only because of the effort and resources 
required but also because they would be relin­
quishing exclusive access to their own raw data 
(and therefore the risk of being “scooped”) for 
the possibility of future requests for reanalysis. 
Even in cases where investigators contemplate 
no further data analyses, they may have con­
cerns about the effort to respond to questions 
about repeat analyses. In any case, additional 
resources would be required, and this is not 
a time of plenty for research in the United 
States or anywhere else. In short, as in all of 
life, there is no free lunch. We already have 
mechanisms for disclosure of data used by the 
U.S. EPA in decision making and even for 
obtaining raw data. It is doubtful that we can 
afford the luxury of having this information 
available for release prior to any request, and it 
is uncertain who should be responsible for the 
cost and effort required to provide it.
We conclude that, as is the case for clinical 
trials, a registry for studies that could handle 
a wide variety of methodologies and methods 
of analysis and provide a more complete and 
Goldman and Silbergeld
152 volume 121 | number 2 | February 2013 • Environmental Health Perspectives
standardized presentation of statistical results 
and other parameters than is possible in the 
peer­reviewed literature would be a tremendous 
resource to society for increasing transparency 
and improving assessments of pesticides and 
chemicals. However, at present, there is no 
evidence that there is a net social benefit to 
requiring collection of and access to raw data 
for all studies utilized by the U.S. EPA prior 
to requests for such data from interested 
parties. As a first step the U.S. EPA, NTP, 
and NLM should begin to generate discussions 
among agencies and with interested outside 
parties, including academic researchers and the 
regulated industry, on the possible crea tion of 
a reporting system for environ mental health 
studies of chemicals and pesticides that would 
systematically collect results and data about 
studies—but not raw data.
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